

Primary stromal sarcoma of the breast

Aleksandra Radovanović, Jasmina Gligorijević, Nikola Živković, Marija Anđelković-Matić

Arch Oncol 2012;20(1-2):24-5.

UDC: 616.988.6:618. 19-006:616.071:616-091.8 DOI: 10.2298/A001202024R

Medical Faculty, Department for Pathology, University of Niš, Serbia

> Correspondence to: Aleksandra Radovanović Dr Zorana Đinđića 48, 18000 Niš, Serbia

aradicevic76@yahoo.com

Received: 01.03.2012 Provisionally accepted: 10.03.2012 Accepted: 20.03.2012

© 2012, Oncology Institute of Vojvodina, Sremska Kamenica

Primary sarcomas of the breast are rare and there are only a few hundred cases reported in the literature; hence, their significance is primarily educational. We report a case of a 57-year old patient who developed breast sarcoma without previous history on any breast diseases.

Key words: Breast Neoplasms; Sarcoma; Diagnosis; Immunohistochemistry; Antigens, CD

INTRODUCTION

Breast cancer is the most common cancer of female population worldwide. In Cancer Statistics 2010, breast cancer remains the heading type of cancer with an estimate of 28% in American women (1). The vast majority of breast cancers are carcinomas, while breast sarcomas are few (2-5). Sarcomas represent less than 1% of all primary breast malignancies end less than 5% of all sarcomas (6-8) and because of their rarity, they are not commonly encountered by the members of medical profession.

Primary breast sarcomas derive from breast mesenchymal tissue. The annual incidental rate is 44.8 new cases per 10 million women (9). There is still no consensus according to the exact definition of breast sarcoma. Some authors excluded cystosarcoma phyllodes from their studies due to its epithelial components (6, 10, 11), but others do not distinguish between other subtypes of breast sarcoma and cystosarcoma because of the similar survival and clinical course (7, 8, 12, 13).

Almost every previous reference on this entity in the literature is in form of small case report series. In almost all cases, patients had been diagnosed clinically as having a breast carcinoma and the correct tissue diagnosis was established by the histology (14-16).

We report a case of primary stromal sarcoma of the breast.

CASE PRESENTATION

A 57-year old female patient presented to the surgical department with a complain of progressive swelling of the left mammary gland without pain. There was no history of previous breast trauma, bleeding, or family history of breast cancer. On examination there was a single 4x5.5x3.5cm mass, firm and nontender in the upper right quadrant. There was slight retraction of the overlaying skin. Excision biopsy was done to confirm the suspicion to

Grossly, the cut section revealed firm, discreetly lobulated, infiltrative unencapsulated gray-white tumor, measuring 4x5.5x3cm. There were no necrotic areas, areas of haemorrhage or calcification. Surgical margins were tumor negative.

Microscopically, hematoxylin and eosin (HE) stained section revealed whorls and nests of spindle cells with mild differences in cellular size. The nuclei were round to oval with marked hyperchromasia. There were neither prominent nucleoli, nor cytoplasmic granules. Focally, tumor cells were round to oval with abundant cytoplasm, separated by delicate fibrous bands with lymphocytic infiltrates and were infiltrating adipous tissue. The suspicion on dedifferentiated carcinoma was not supported by immunohistochemical findings. The APAP method was used to analyze: vimentin, desmin,

cytokeratin, MAC, pan T, pan B, proliferating cell nuclear antigen (PCNA), epithelial membrane antigen (EMA), CD34, CD68 and S100. The tumor was found to be vimentine and CD68 positive. Very strong expression for PCNA was demonstrated (Figure 1).




Figure 1. A - Tumor is composed of whorls and nests of spindle cells. Trichrome x40; B - Vimentin x40 was strongly positive; C - Strong immunoreactivity to CD68 x100; D - Cytokeratin staining was negative x100; E - Actin x 20 was negative; F - S-100 x 20 was negative

DISCUSSION

Primary sarcomas of the breast are rare and there are only a few hundred cases reported in the literature. Cystosarcoma phyllodes are much more common and their behavior, management and treatment are different from pure sarcoma. The reported case was the first stromal sarcoma diagnosed in our laboratory during the period of 32 years. The defect in experience was prevailed over by using appropriate antibodies for immunohistochemical method as recommended (15). The controversy still exists on the term "stromal sarcoma". Berg end coworkers have unified all breast sarcomas other then cystosarcoma phyllodes under stromal sarcoma to indicate their origin from breast stroma (17). In 1985, Callery et al. proposed the term "stromal sarcoma" for tumors arising from specialized hormone sensitive breast stroma. It is now recommended to use histological description by cell of origin of the neoplasm (18). The most common sub-types of breast sarcomas are: malignant fibrous histiocytoma, fibrous sarcoma, angiosarcoma and spindle cell sarcoma. Several other sub-types (leiomyosarcoma, liposarcoma, rhabdomyosarcoma, osteosarcoma, chondrosarcoma, synovial sarcoma and neurosarcoma) have been described as smaller percentages of case series or as case reports. (5, 8, 14). The presenting case is stromal sarcoma-fibrous sarcoma, according to the cell of origin.

Although rare, one must have in mind the possibility of such neoplasm in the breast any time there are spindle cells in the sections of the tumor. The breast is the place of metastatic sarcomas (19, 20) as well as the sarcomas secondary to radiotherapy (21).

The risks of developing breast sarcoma are largely unknown, but those often proposed are: external beam radiation of the breast or chest wall; chronic lymphedema of the breast and arm (especially for angiosarcomas); pre-existing fibroadenomata or hereditary diseases, like neurofibromatosis or Li-Fraumeni syndrome (22).

It appears that breast sarcomas behave like extremity sarcomas and hence, it is rational for using the same treatment protocol (15, 22). The first therapeutical line is surgical resection with postoperative radiotherapy with or without chemotherapy. In the present case, the conservation of the breast was done with radiotherapy and without chemotherapy. The patient was followed for 22 months and was in good condition.

Conflict of interest

We declare no conflicts of interest.

REFERENCES

- 1 American Cancer Society: Jemal A, Siegel R, Xu J, Ward E Cancer Statistics 2010. Ca Cancer J Clin. 2010;60:277-300.
- 2 de Mello RA, Figueiredo P, Marques M, Sousa G, Carvalho T, Gervásio HJ. Concurrent breast stroma sarcoma and breast carcinoma: a case report. *Med Case Reports*. 2010;4:414.
- 3 McPherson K, Steel CM, Dixon JM. ABC of breast diseases, breast cancer epidemiology, risk factors and genetics. BMJ. 2000;321:624-8.
- 4 Grimer R. Size matters for sarcomas. Ann R Coll Surg Engl. 2006;88:519-24.
- **5** Adem C, Reynolds C, Ingle JN, Nascimento AG. Primary breast sarcoma: Clinicopathologic series from the Mayo Clinic and review of the literature. *Br J Cancer*. 2004;91:237-41.
- **6** Pollard SG, Marks PV, Temple LN, Thompson HH. Breast sarcoma. A clinicopathologic review of 25 cases. *Cancer*.1990;66(5):941-4.
- 7 Terrier P, Terrier-Lacombe MJ, Mouriesse H, Friedman S, Spielmann M, Contesso G. Primary breast sarcoma: a review of 33 cases with immunohistochemistry and prognostic factors. *Breast Cancer Res Treat.* 1989;13(1):39-48.
- 8 McGowan TS, Cummings BJ, O'Sullivan B, Catton CN, Miller N, Panzarella T. An analysis of 78 breast sarcoma patients without distant metastases at presentation. Int J Radiat Oncol Biol Phys. 2000;46(2):383-90.
- 9 May DS, Stroup NE. The incidence of sarcomas of the breast among women in the United States, 1973-1986. Plast Reconstr Surg. 1991;87(1):193-4.
- 10 Fields RC, Aft RL, Gillanders WE, Eberlein TJ, Margenthaler JA. Treatment and outcomes of patients with primary breast sarcoma. Am J Surg. 2008;196(4):559-61.

- 11 Bousquet G, Confavreux C, Magné N, de Lara CT, Poortmans P, Senkus E, et al. Outcome and prognostic factors of the breast sarcoma: a multicenter study from the rare cancer network. *Radiother Oncol.* 2007;85(3):355-61.
- 12 Lattes R. Sarcomas of the breast. Int J Radiat Oncol Biol Phys. 1978;4(7-8):705-8.
- 13 McGregor GI, Knowling MA, Este FA. Sarcoma and cystosarcoma phyllodes tumors of the breast: a retrospective review of 58 cases. Am J Surg. 1994;167(5): 477-80.
- 14 Ogundiran TO, Ademola SA, Oluwatosin OM, Akang EE, Adebamovo CA. Primary osteogenic sarcoma of the breast. World J Sura Oncol. 2006:4:90.
- **15** Pandey M, Mathew A, Abraham EK, Rajan B. Primary sarcoma of the breast. *J Surg Oncol*. 2004;87(3):121-5.
- 16 Dhingra KK, Mandal S, Roy S, Khurana N. Malignant peripheral nerve sheath tumor of the breast: case report. World J Surg Oncol. 2007;5:142-5.
- 17 Berg JW, Decrosse JJ, Fracchia AA, Farrow J. Stromal sarcomas of the breast. A unified approach to connective tissue sarcomas other then cystosarcoma phyllodes. *Cancer.* 1962;15:418-24.
- 18 Al-Nafussi A. Spindle cell tumors of the breast-practical approach to diagnosis. Histopathology. 1999;35:1-13.
- 19 Taillibert S, Spano JP, Genestic C, Khayat D. A mesocolic leiomyosarcoma metastatic to the breast: Case report and review of literature. Anticancer Res. 20:4867-9.
- **20** Lin CH, Yeh CN, Chen MF. Breast metastasis from uterine leiomyosarcoma: A case report. *Arch Gynecol Obstet.* 267:233-5.
- 21 Barrow BJ, Janjan NA, Gutman H, Benjamin RS, Allen P, Romsdahl MM, et al. Role of radiotherapy in sarcoma of the breast-a retrospective review of the MD Anderson Experience. *Radioth Oncol.* 1999;52(2):173-8.
- 22 Al-Benna S, Pogemann K, Steinau HU, Steinstraesser L. Diagnosis and management of primary breast sarcoma. Breast Cancer Res Treat. 2010;122:619-26.